StoryRegulatory
China's NMPA approves Nerivio for acute migraine in adults, with partner Pier 88 Health
Pier 88 Health and Theranica announced China's approval of Nerivio, the first remote electrical neuromodulation wearable for migraine approved there. The certificate was issued on 11 August 2025; the initial indication is acute treatment in adults.
- About 130 million people in China are estimated to have migraine
- Expansion to other indications and age groups is planned
- Key Theranica markets: US, Europe, India, South Africa and now China